CA2647360A1 - Procedes et compositions de dissuasion d'abus de produits pharmaceutiques a administration orale - Google Patents
Procedes et compositions de dissuasion d'abus de produits pharmaceutiques a administration orale Download PDFInfo
- Publication number
- CA2647360A1 CA2647360A1 CA002647360A CA2647360A CA2647360A1 CA 2647360 A1 CA2647360 A1 CA 2647360A1 CA 002647360 A CA002647360 A CA 002647360A CA 2647360 A CA2647360 A CA 2647360A CA 2647360 A1 CA2647360 A1 CA 2647360A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- esters
- irritant
- composition
- ethoxylates
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract 22
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 229940127557 pharmaceutical product Drugs 0.000 title 1
- 238000011010 flushing procedure Methods 0.000 claims abstract 7
- 239000003795 chemical substances by application Substances 0.000 claims abstract 4
- 229920000642 polymer Polymers 0.000 claims abstract 3
- -1 polyoxyethylene Polymers 0.000 claims 52
- 231100000021 irritant Toxicity 0.000 claims 25
- 239000002085 irritant Substances 0.000 claims 25
- 210000001519 tissue Anatomy 0.000 claims 15
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 8
- 150000001298 alcohols Chemical class 0.000 claims 8
- 150000001412 amines Chemical class 0.000 claims 8
- 229910019142 PO4 Inorganic materials 0.000 claims 6
- 235000014113 dietary fatty acids Nutrition 0.000 claims 6
- 229930195729 fatty acid Natural products 0.000 claims 6
- 239000000194 fatty acid Substances 0.000 claims 6
- 150000002334 glycols Chemical class 0.000 claims 6
- 235000021317 phosphate Nutrition 0.000 claims 6
- 230000001225 therapeutic effect Effects 0.000 claims 6
- 239000000499 gel Substances 0.000 claims 5
- 239000004166 Lanolin Chemical class 0.000 claims 4
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical class OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 claims 4
- 230000000202 analgesic effect Effects 0.000 claims 4
- 150000002148 esters Chemical class 0.000 claims 4
- 150000004665 fatty acids Chemical class 0.000 claims 4
- 229940039717 lanolin Drugs 0.000 claims 4
- 235000019388 lanolin Nutrition 0.000 claims 4
- 229920001223 polyethylene glycol Polymers 0.000 claims 4
- 150000004760 silicates Chemical class 0.000 claims 4
- 150000003871 sulfonates Chemical class 0.000 claims 4
- 239000002518 antifoaming agent Substances 0.000 claims 3
- 239000002738 chelating agent Substances 0.000 claims 3
- 239000003599 detergent Substances 0.000 claims 3
- 239000002270 dispersing agent Substances 0.000 claims 3
- 239000003974 emollient agent Substances 0.000 claims 3
- 239000003995 emulsifying agent Substances 0.000 claims 3
- 239000003623 enhancer Substances 0.000 claims 3
- 239000004088 foaming agent Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000002904 solvent Substances 0.000 claims 3
- 239000000080 wetting agent Substances 0.000 claims 3
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims 2
- 229920000858 Cyclodextrin Polymers 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical class OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 2
- 239000005642 Oleic acid Substances 0.000 claims 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims 2
- 239000002202 Polyethylene glycol Chemical class 0.000 claims 2
- 239000004721 Polyphenylene oxide Substances 0.000 claims 2
- 235000021355 Stearic acid Nutrition 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 2
- 150000003973 alkyl amines Chemical class 0.000 claims 2
- 125000005210 alkyl ammonium group Chemical group 0.000 claims 2
- 150000008055 alkyl aryl sulfonates Chemical class 0.000 claims 2
- 125000005599 alkyl carboxylate group Chemical group 0.000 claims 2
- 150000005215 alkyl ethers Chemical class 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 150000008051 alkyl sulfates Chemical class 0.000 claims 2
- 125000005211 alkyl trimethyl ammonium group Chemical group 0.000 claims 2
- 125000005233 alkylalcohol group Chemical group 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- 235000019270 ammonium chloride Nutrition 0.000 claims 2
- 150000003868 ammonium compounds Chemical class 0.000 claims 2
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 claims 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 150000001735 carboxylic acids Chemical class 0.000 claims 2
- 229920001577 copolymer Polymers 0.000 claims 2
- 229940097362 cyclodextrins Drugs 0.000 claims 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims 2
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 claims 2
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 claims 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- 150000002170 ethers Chemical class 0.000 claims 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 2
- 239000003925 fat Substances 0.000 claims 2
- 150000002306 glutamic acid derivatives Chemical class 0.000 claims 2
- 150000002314 glycerols Chemical class 0.000 claims 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 239000000787 lecithin Substances 0.000 claims 2
- 235000010445 lecithin Nutrition 0.000 claims 2
- 150000004702 methyl esters Chemical class 0.000 claims 2
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical class C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 claims 2
- 229920000847 nonoxynol Polymers 0.000 claims 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 2
- CXQXSVUQTKDNFP-UHFFFAOYSA-N octamethyltrisiloxane Chemical class C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C CXQXSVUQTKDNFP-UHFFFAOYSA-N 0.000 claims 2
- 229920002113 octoxynol Polymers 0.000 claims 2
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 claims 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 2
- 229920001542 oligosaccharide Polymers 0.000 claims 2
- 239000000014 opioid analgesic Substances 0.000 claims 2
- 150000007524 organic acids Chemical class 0.000 claims 2
- 235000005985 organic acids Nutrition 0.000 claims 2
- 239000010702 perfluoropolyether Substances 0.000 claims 2
- 229940083254 peripheral vasodilators imidazoline derivative Drugs 0.000 claims 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims 2
- 150000003014 phosphoric acid esters Chemical class 0.000 claims 2
- 239000010773 plant oil Chemical class 0.000 claims 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims 2
- 229920001748 polybutylene Polymers 0.000 claims 2
- 229920000570 polyether Polymers 0.000 claims 2
- 229920005606 polypropylene copolymer Polymers 0.000 claims 2
- 229920001451 polypropylene glycol Polymers 0.000 claims 2
- 229920001296 polysiloxane Chemical class 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 125000001453 quaternary ammonium group Chemical group 0.000 claims 2
- 231100000323 severe irritant Toxicity 0.000 claims 2
- 229940083037 simethicone Drugs 0.000 claims 2
- 239000008117 stearic acid Substances 0.000 claims 2
- 150000003445 sucroses Chemical class 0.000 claims 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims 2
- 239000003760 tallow Substances 0.000 claims 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical class NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims 2
- 230000000903 blocking effect Effects 0.000 claims 1
- 210000001180 ethmoid sinus Anatomy 0.000 claims 1
- 210000001214 frontal sinus Anatomy 0.000 claims 1
- 210000004086 maxillary sinus Anatomy 0.000 claims 1
- 210000004400 mucous membrane Anatomy 0.000 claims 1
- 210000003718 sphenoid sinus Anatomy 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 2
- 229940088679 drug related substance Drugs 0.000 abstract 2
- 239000002552 dosage form Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 239000006186 oral dosage form Substances 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Botany (AREA)
- Zoology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78244806P | 2006-03-15 | 2006-03-15 | |
| US60/782,448 | 2006-03-15 | ||
| PCT/US2007/006519 WO2007106550A2 (fr) | 2006-03-15 | 2007-03-14 | Procédés et compositions de dissuasion d'abus de produits pharmaceutiques à administration orale |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2647360A1 true CA2647360A1 (fr) | 2007-09-20 |
| CA2647360C CA2647360C (fr) | 2012-05-15 |
Family
ID=38510088
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2647360A Expired - Fee Related CA2647360C (fr) | 2006-03-15 | 2007-03-14 | Procedes et compositions de dissuasion d'abus de produits pharmaceutiques a administration orale |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1993519A4 (fr) |
| AU (1) | AU2007225101A1 (fr) |
| CA (1) | CA2647360C (fr) |
| IL (1) | IL193766A0 (fr) |
| WO (1) | WO2007106550A2 (fr) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010069050A1 (fr) * | 2008-12-16 | 2010-06-24 | Labopharm Inc. | Composition à libération contrôlée prévenant un mésusage |
| US8691270B2 (en) | 2007-12-17 | 2014-04-08 | Paladin Labs Inc. | Misuse preventative, controlled release formulation |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1429744A1 (fr) | 2001-09-21 | 2004-06-23 | Egalet A/S | Systeme a liberation de polymere de morphine |
| US20040234602A1 (en) | 2001-09-21 | 2004-11-25 | Gina Fischer | Polymer release system |
| US8877241B2 (en) | 2003-03-26 | 2014-11-04 | Egalet Ltd. | Morphine controlled release system |
| AU2008258596B2 (en) | 2007-06-04 | 2013-02-14 | Egalet Ltd | Controlled release pharmaceutical compositions for prolonged effect |
| AU2015200313B2 (en) * | 2007-12-17 | 2016-12-01 | Alpharma Pharmaceuticals, Llc | Pharmaceutical composition |
| WO2009079521A1 (fr) * | 2007-12-17 | 2009-06-25 | Alpharma Pharmaceuticals, Llc | Composition pharmaceutique |
| EP2393484A1 (fr) | 2009-02-06 | 2011-12-14 | Egalet Ltd. | Composition à libération immédiate résistant à une maltraitance par prise d'alcool |
| AU2010265213B2 (en) | 2009-06-24 | 2012-08-23 | Egalet Ltd. | Controlled release formulations |
| EP2877161A1 (fr) | 2012-07-06 | 2015-06-03 | Egalet Ltd. | Compositions pharmaceutiques de dissuasion d'abus à libération contrôlée |
| CA2919892C (fr) | 2013-08-12 | 2019-06-18 | Pharmaceutical Manufacturing Research Services, Inc. | Comprime extrude anti-abus a liberation immediate |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| WO2015095391A1 (fr) | 2013-12-17 | 2015-06-25 | Pharmaceutical Manufacturing Research Services, Inc. | Comprimé extrudé anti-abus à libération prolongée |
| EP3169315B1 (fr) | 2014-07-17 | 2020-06-24 | Pharmaceutical Manufacturing Research Services, Inc. | Forme posologique remplie de liquide anti-abus à libération immédiate |
| US9132096B1 (en) | 2014-09-12 | 2015-09-15 | Alkermes Pharma Ireland Limited | Abuse resistant pharmaceutical compositions |
| WO2016064873A1 (fr) | 2014-10-20 | 2016-04-28 | Pharmaceutical Manufacturing Research Services, Inc. | Forme galénique anti-abus de remplissage de liquide à libération prolongée |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10250084A1 (de) * | 2002-10-25 | 2004-05-06 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
| US7201920B2 (en) * | 2003-11-26 | 2007-04-10 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of opioid containing dosage forms |
| US20060110327A1 (en) * | 2004-11-24 | 2006-05-25 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of orally administered pharmaceutical products |
| US20060177380A1 (en) * | 2004-11-24 | 2006-08-10 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of orally administered pharmaceutical products |
-
2007
- 2007-03-14 CA CA2647360A patent/CA2647360C/fr not_active Expired - Fee Related
- 2007-03-14 AU AU2007225101A patent/AU2007225101A1/en not_active Abandoned
- 2007-03-14 WO PCT/US2007/006519 patent/WO2007106550A2/fr active Application Filing
- 2007-03-14 EP EP07753168A patent/EP1993519A4/fr not_active Withdrawn
-
2008
- 2008-08-28 IL IL193766A patent/IL193766A0/en unknown
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8691270B2 (en) | 2007-12-17 | 2014-04-08 | Paladin Labs Inc. | Misuse preventative, controlled release formulation |
| US8920833B2 (en) | 2007-12-17 | 2014-12-30 | Paladin Labs Inc. | Misuse preventative, controlled release formulation |
| US8920834B2 (en) | 2007-12-17 | 2014-12-30 | Paladin Labs Inc. | Misuse preventative, controlled release formulation |
| WO2010069050A1 (fr) * | 2008-12-16 | 2010-06-24 | Labopharm Inc. | Composition à libération contrôlée prévenant un mésusage |
| US8927013B2 (en) | 2008-12-16 | 2015-01-06 | Paladin Labs Inc. | Misuse preventative, controlled release formulation |
| US8927014B2 (en) | 2008-12-16 | 2015-01-06 | Paladin Labs Inc. | Misuse preventative, controlled release formulation |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1993519A2 (fr) | 2008-11-26 |
| EP1993519A4 (fr) | 2011-12-21 |
| AU2007225101A1 (en) | 2007-09-20 |
| WO2007106550A3 (fr) | 2008-06-12 |
| IL193766A0 (en) | 2011-08-01 |
| CA2647360C (fr) | 2012-05-15 |
| WO2007106550A2 (fr) | 2007-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2647360A1 (fr) | Procedes et compositions de dissuasion d'abus de produits pharmaceutiques a administration orale | |
| EP2934480B1 (fr) | Compositions germicides comprenant un mélange à base d'acide carboxylique et utilisation comme désinfectant topique | |
| US8569373B2 (en) | Compositions comprising A C2-C14 carboxylic acid and a surfactant for treating hoof diseases | |
| AU2002337677B2 (en) | Wipe formulation | |
| US11166912B2 (en) | Orally administrable composition | |
| Puratchikody et al. | Buccal drug delivery: past, present and future-a review | |
| WO2006058249A3 (fr) | Procedes et compositions destines a decourager l'abus de produits pharmaceutiques administres oralement | |
| US20200276315A1 (en) | Povidone-iodine topical composition | |
| JP2010524976A (ja) | 抗菌性組成物、製品及び使用方法 | |
| CN102711732A (zh) | 化妆用泡沫 | |
| AU2002337677A1 (en) | Wipe formulation | |
| CA2805749A1 (fr) | Compositions pharmaceutiques et leurs procedes d'utilisation | |
| JP2014530242A5 (fr) | ||
| JP2022031733A (ja) | 炎症性皮膚疾患及び皮膚病変を処置するための酸素化コレステロール硫酸（ｏｃｓ）の使用 | |
| JP2009502985A5 (fr) | ||
| DK1409022T3 (da) | Farmaceutisk moussesammensætning omfattende salicylsyre | |
| ES2388236T3 (es) | Procedimiento de solubilización de metronidazol con la ayuda de niacinamida y de dos glicoles, disolución así obtenida | |
| WO2008057423A1 (fr) | Trousses contenant des tampons de peroxyde de benzoyle et une composition de réparation de barrière cutanée, et préparations et méthodes d'utilisation associées | |
| JP2020011953A (ja) | 水解性外用シート剤及び外用シート剤の水解性向上方法 | |
| US20120301409A1 (en) | Homeopathic composition and method for the treatment of skin irritations and other skin diseases | |
| CA2499900A1 (fr) | Vaporisations nasales seches | |
| Syed et al. | Buccal mucoadhesive based drug delivery devices | |
| JP2007246459A5 (fr) | ||
| US20220226240A1 (en) | Orally administrable composition | |
| JP7060526B2 (ja) | ベンジダミンを含む医薬組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20190314 |